Jaguar Health (JAGX) Income towards Parent Company (2014 - 2026)
Jaguar Health's (JAGX) quarterly Income towards Parent Company came in at $8.7 million in Q1 2026, up 182.32% year-on-year from $3.1 million in Q1 2025, and up 137.61% on a QoQ basis from -$23.2 million in Q4 2025.
Jaguar Health (JAGX) Income towards Parent Company (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Income towards Parent Company data on file, last reported at $8.7 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 182.32% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was -$34.7 million, a 14.33% increase from a year earlier, with the FY2025 full-year figure at -$54.0 million, down 37.57% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $8.7 million, up from -$23.2 million in the prior quarter.
- Over the last five years, Income towards Parent Company for JAGX reached as high as $8.7 million in Q1 2026 and fell as low as -$23.2 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$10.3 million across 5 years, with a median of -$10.0 million in 2024.
- Across the five-year window, Income towards Parent Company plunged 126.63% in 2025 and jumped 182.32% in 2026, its largest moves.
- Year by year, Income towards Parent Company stood at -$8.2 million in 2022, then declined by 13.08% to -$9.3 million in 2023, then decreased by 9.94% to -$10.2 million in 2024, then plunged by 126.63% to -$23.2 million in 2025, then surged by 137.61% to $8.7 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $8.7 million in Q1 2026, -$23.2 million in Q4 2025, and -$9.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - |
| 3 | BeOne Medicines | 473.44 Bn | 468.65 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.69 Bn | 116.45 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.62 Bn | 62.86 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - |
| 7 | Argenx Se | 54.57 Bn | 49.38 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.11 Bn | 35.10 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.19 Bn | 36.19 Bn | - |
| 10 | Jaguar Health | 523,524.81 | -9.54 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.72 Mn |
| Dec 31, 2025 | -23.19 Mn |
| Sep 30, 2025 | -9.65 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -9.63 Mn |
| Mar 31, 2024 | -9.37 Mn |
| Dec 31, 2023 | -9.31 Mn |
| Sep 30, 2023 | -7.90 Mn |
| Jun 30, 2023 | -12.29 Mn |
| Mar 31, 2023 | -12.40 Mn |
| Dec 31, 2022 | -8.23 Mn |
| Sep 30, 2022 | -12.61 Mn |
| Jun 30, 2022 | -9.39 Mn |
| Mar 31, 2022 | -18.16 Mn |
| Dec 31, 2021 | -14.32 Mn |
| Sep 30, 2021 | -12.19 Mn |
| Jun 30, 2021 | -14.08 Mn |